CGCI supports cutting-edge genomics research on adult and pediatric cancers. Researchers develop and apply advanced sequencing and other genome-based methods to identify novel genetic abnormalities in tumors. The extensive genetic profiles generated by CGCI may inform better cancer diagnosis and treatment.
The NCI’s Office of Cancer Genomics (OCG), within the Center for Cancer Genomics, aims to advance and accelerate genomics science and enhance the understanding of the molecular mechanisms of cancer. In fulfilling this mission, OCG programs generate data and resources, and develop tools that can be broadly used by the research community to efficiently improve cancer prevention, early detection, diagnosis, and treatment.
CTD2 bridges the gap between the enormous volumes of data generated by genomic characterization studies and the ability to use these data for the development of human cancer therapeutics. It specializes in computational and functional genomics approaches critical for translating next-generation sequencing data, as well as high-...
TARGET applies a comprehensive genomic approach to determine molecular changes that drive childhood cancers. Investigators form a collaborative network to facilitate discovery of molecular targets and translate those findings into the clinic. TARGET is managed by NCI’s Office of Cancer Genomics and Cancer Therapy Evaluation Program.
News & Publications
Improved biomarker tests are required to minimize overdiagnosis and overtreatment of breast cancers. A number of pathologic criteria have been established to differentiate indolent or aggressive behavior, such as Nottingham grade of cancer cells. However, the effects of the tumor...
Purpose: To investigate the role and significance of TP53 mutation in...
September 28, 2016
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
The common participation of oncogenic KRAS proteins in many of the most lethal human cancers,...